Zifanocycline  (Synonyms: KBP-7072)

Zifanocycline (KBP-7072) is a semisynthetic third-generation aminomethylcycline antibiotic that inhibits the normal function of the bacterial ribosome. Zifanocycline exhibits a broad spectrum of in vitro antibacterial activity against Gram-positive and Gram-negative bacteria, including many multidrug-resistant pathogens. Zifanocycline is available in both oral and injectable formulations. Zifanocycline can be used for the research of acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, and complicated intra-abdominal infections^[1][2].

Zifanocycline (KBP-7072) demonstrates MIC₉₀ values of <1 μg/ml across a range of pathogens, including typical and atypical pathogens associated with community-acquired bacterial pneumonia (CABP)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Sprague-Dawley (SD) rats, beagle dogs, and CD-1 mice, KBP-7072 demonstrated a linear PK profile after the administration of single oral and i.v. and multiple oral doses. The oral bioavailability ranged from 12% to 32%. The mean time to maximum concentration (T max) ranged from 0.5 to 4 h, and the mean half-life ranged from approximately 6 to 11 h. The administration of oral doses in the fed state resulted in marked reductions in the maximum plasma concentration (C max) and the area under the concentration-time curve (AUC) compared with dosing in fasted animals. The mean bound fractions of KBP-7072 were 77.5%, 69.8%, 64.5%, 69.3%, and 69.2% in mouse, rat, dog, monkey, and human plasma, respectively^[1].
KBP-7072 exhibits dose-dependent potent activity against selected methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) S. aureus strains over the dose range studied (0.25 to 64 mg/kg/6 h) in neutropenic murine pneumonia infection model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

552.62

C₂₉H₃₆N₄O₇

1420294-56-9

O[C@]12[C@](C[C@@]3([H])C(C(C4=C(O)C(CN5CC6C(C6)C5)=CC(N(C)C)=C4C3)=O)=C2O)([H])[C@@H](C(O)=C(C1=O)C(N)=O)N(C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Tan X, et al. Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models. Antimicrob Agents Chemother. 2020;64(6):e00488-20. Published 2020 May 21.  [Content Brief]

  [2]. Lepak AJ, et al. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2019;63(3):e02404-18. Published 2019 Feb 26.  [Content Brief]